Cairns Hospital
Cairns Hospital
Cairns, Queensland, Australia18 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma | DNA Virus Infections, Infections, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Tumor Virus Infections, adenocarcinoma, carcinoma, cutaneous neuroendocrine carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, viral infectious disease | Active, not recruiting | Phase 2 | 2026-10-07 | NCT04291885 | |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Arterial Occlusive Diseases, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infarction, Male Urogenital Diseases, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, ischemic disease, kidney disorder, kidney failure, metabolic disease, myocardial infarction, myocardial ischemia, peripheral arterial disease, peripheral vascular disease, urinary system disorder, vascular disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-21 | NCT05485961 | |
| Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-09-10 | NCT06345079 | |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2026-09-09 | NCT05633654 | |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2026-09-01 | NCT06712355 | |
| Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, hyperphosphatemia, kidney disorder, kidney failure, metabolic disease, phosphorus metabolism disease, urinary system disorder | Recruiting | Not applicable | 2026-08-26 | NCT03573089 | |
| A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Disease Attributes, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 | 2026-08-21 | NCT06769698 | |
| A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-06-17 | NCT04961996 | |
| Duration of Anti-PD-1 Therapy in Metastatic Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 3 | 2026-06-09 | NCT02821013 | |
| Staphylococcus Aureus Network Adaptive Platform Trial | Bacterial Infections and Mycoses, Infections, bacterial infectious disease, gram-positive bacterial infections, staphylococcal infection | Recruiting | Phase 4 | 2026-05-06 | NCT05137119 | |
| SODium BICarbonate for Metabolic Acidosis in the ICU | Acid-Base Imbalance, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, acidosis disorder, metabolic acidosis, metabolic disease | Active, not recruiting | Phase 3 | 2026-03-27 | NCT05697770 | |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | skin squamous cell carcinoma | Active, not recruiting | Phase 3 | 2026-03-27 | NCT03969004 | |
| Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis | Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Shock, Systemic Inflammatory Response Syndrome, toxic shock syndrome | Active, not recruiting | Phase 3 | 2026-03-17 | NCT04569942 | |
| The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. | Diabetes Complications, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Urogenital Diseases, autoimmune disease, cardiovascular disorder, diabetes mellitus, diabetic kidney disease, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, glucose metabolism disease, immune system disorder, kidney disorder, metabolic disease, retinal disorder, type 1 diabetes mellitus, urinary system disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-01-20 | NCT01320345 | |
| IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, metastatic melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 3 | 2025-08-28 | NCT05155254 | |
| Better Evidence and Translation for Calciphylaxis | Nutritional and Metabolic Diseases, calcinosis, calciphylaxis, calcium metabolic disease, metabolic disease | Recruiting | Phase 3 | 2025-08-13 | NCT05018221 | |
| ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients | Brain Injuries, Traumatic, Craniocerebral Trauma, Multiple Trauma, Wounds, Nonpenetrating, Wounds, Penetrating, brain disorder, brain injury, central nervous system disorder, injury, nervous system disorder, nervous system injury | Recruiting | Phase 3 | 2025-07-16 | NCT04588311 | |
| Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients | Solid Tumor, Adult | Recruiting | Phase 2 | 2024-11-15 | NCT06003621 |